Introduction

Antiviral drugs are used for treating viral infection such as human immunodeficiency virus (HIV), hepatitis, influenza and novel corona virus. Anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is efficacious against a varying range of viruses. These drugs inhibit the development of viruses into host. Based on current scenario most of the viral diseases are self-limited illnesses that do not require specific antiviral therapy.

Some of the driving factor in the market for antivirals drugs are increase in prevalence of infectious diseases, growing research and development for new molecule formulation, increasing demand for combination therapies, and topical administration routes. The increasing number of pipeline drugs such as Rilpivirine, Rapiacta, Vicriviroc, and Elvitegravir, by various competitive players are contributing to boost the market, adding to this increase in awareness among population, rise in number of HIV infected patients, dueto COVID-19 outbreak the demand for anti-viral drugs is increased.

The number of Patent drugs will expire that leads to growth and development of the generic therapies is anticipated to grow the market in coming years. Moreover, there are some other factors that drive the anti-viral drug market are increase in spending on health care infrastructure and increased in high efficacy drugs is anticipated to grow the market

Apart from this there are some factors that hinder the growth of anti-viral drug market such as high cost associated with R&D and various government policies and growing awareness among population about precautions are some restrains to the growth of market. According to WebMD 60-70% of U.S population got infected by cytomegalovirus and are at high risk.

Segmentation

The Antiviral Drugs Market segmentation is based on drug class, application, type and region.

Drug Class Outlook

Based on drug class the market is segmented in to DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.  The anti-viral drugs are effective against multiple range of viruses.  Reverse transcriptase inhibitors is effective in slowing down the spread of infection, due to that demand for RTI is more into market.

Application outlook:

Based on applicaton, the market is segmented into HIV, Hepatitis, Influenza. The use of antiviral drug is found more in treatment of common viral diseases, including, HIV/AIDS, Hepatitis, Herpes, Influenza, and several others. It had determined that, in 2019, the significant utilizations of antiviral medications, HIV/AIDS Therapeutics and Hepatitis represented over 73% in the worldwide. Hepatitis C remained the lucrative application for antiviral drugs whose growth considerably go down in a few years. However, after this slow down HIV drug become the dominant segment to grow the market. Adding to this increasing case of influenza virus epidemics the market witness gradual growth into overall industry.

Type outlook:

Based on type, the antiviral drugs market is segmented into branded and generic. The branded drug segment dominated the market due to assumption of safety associated with branded drugs consumption as compared to generic drugs. The generic segment is anticipated to grow in coming years owing to low price of generic drug, increasing adoption of generic medicine by consumers and patent expiry of branded drug.

Region outlook:

Based on the region, the global acetone market has been segmented by North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, & Rest of the World. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. Asia Pacific region is expected to grow owing to factors such as developed and strong presence of generic drugs, improving economy, increasing number of patients provide growth opportunities in this region.

Major Players

Some of the key players in global anti-viral drugs market, include F. Hoffmann-La Roche AG, Gilead, GlaxoSmithKline, AbbVie, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

Key Development

• March 2020:- The WHO announced that Gilead's drug Remdesivir is showing signs that the drug may be able help treat the novel Coronavirus.
• December 2019: - Merck acquired ArQule, making ArQule a wholly-owned subsidiary of Merck. Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases.
• December 2019: - Roche concluded the acquisition of Spark Therapeutics, Inc. for strengthening presence in gene therapy. The Spark to continue its operations in Philadelphia as an independent company within the Roche Group. The companies together will improve the lives of the patients through innovative gene therapies.

What Does This Report Provide?

This report provides a detailed understanding of the global anti-viral drug market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Market Segmentation:

By Drug Class

• DNA Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Neuraminidase Inhibitors
• Others

By Application

• HIV
• Hepatitis
• Influenza

By Type

• Branded
• generic

By Region:

• North America Antiviral Drugs Market
  • By Country (US, Canada, Mexico)
  • By Drug Class
  • By Application
  • By Type
• Western Europe Antiviral Drugs Market
  • By Country (Germany, Russia, UK, France, Italy, Spain, Rest of Western Europe)
  • By Drug Class
  • By Application
  • By Type
• Asia Pacific Antiviral Drugs Market
  • By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
  • By Drug Class
  • By Application
  • By Type
• Middle East & Africa Antiviral Drugs Market
  • By Country (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa)
  • By Drug Class
  • By Application
  • By Type
• South America Antiviral Drugs Market
  • By Country (Brazil, Argentina, Colombia, Rest of South America)
  • By Drug Class
  • By Application
  • By Type

Reasons to Buy This Report:

• Market size estimation of the anti-viral drug market on a regional and global basis
• Unique research Usage for market size estimation and forecast
• Profiling of major companies operating in the market with key developments
• Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:

We provide customization of the study to meet specific requirements:

• By Segment
• By Sub-segment
• By Region/Country

For more information, contact: [email protected]